Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tyrosine Kinase Inhibitors in Pediatric ALL

Hematology 2017; 2017 Dec 8; Silverman, et al

Nonchemotherapeutic therapies such as tyrosine kinase inhibitors are proving valuable in children and adolescents with acute lymphoblastic leukemia, according to a recent review. The authors note that although current treatments confer favorable prognosis, multiagent chemotherapy regimens are linked with complications, and therapy for relapsed disease is intensive and often not optimal.

The review goes on to summarize promising results from recent clinical trials of novel nonchemotherapeutic treatments, which can be used in conjunction with, or even in place of, current regimens.


Silverman L. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia. Hematology 2017. 2017;2017(1):259-264. doi:10.1182/asheducation-2017.1.259.